DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Expanded access
Expanded access
FDA and Marijuana: Questions and Answers 1
FDA Comments on CBD in Foods
Regulating Rare Disease: Safely Facilitating Access to Orphan Drugs
Federal Register/Vol. 74, No. 155/Thursday, August 13, 2009
Bulletin
Vaccines, Diagnostics, and Treatments): Frequently Asked Questions
Existing Regulatory Pathways and Processes Relevant to COVID-19
Expanded Access Programme: Looking for a Common Definition Antonella Iudicello1, Lucia Alberghini2*, Giulia Benini2 and Paola Mosconi3
Dave Klein Is Extremely Committed to Flying High and Running Fast
An Open-Label, Multicenter, Expanded Access Study Of
The Surprising Reach of FDA Regulation of Cannabis Even After Descheduling
Study Protocol
Alternative Drug Approval Pathways
Emergency Use, Compassionate Use & Expanded Access Programs
Access to New Medications for the Treatment of Drug-Resistant Tuberculosis
Penn Medicine Remdesivir Emergency Use Authorization
Experiences of Caregivers of Children with Spinal Muscular Atrophy
State “Right to Try” Acts: a Good Start, but a Federal Act Is Necessary
Top View
New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges
Off-Label, Approved Orphan, and Expanded Access (Compassionate Use) Drugs
Treatments Considered for COVID-19 (Updated July 6, 2020)
Nusinersen Use in Spinal Muscular Atrophy Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
Remdesivir Distribution, Reporting and Use for Treatment of Patients
An Activist's Guide to Regulatory Issues
Early Access to Unapproved Medicines in the United States and France
Irb-Policies-And-Procedures.Pdf
Downloadable-Public-Use-Files/Provider-Of-Services
Access to Investigational Drugs
The Surprising Reach of FDA Regulation of Cannabis Even After Rescheduling, 68 Am